Two-week supplementation of Bifidobacterium adolescentis iVS-1 reduces symptoms associated with lactose intolerance in lactose maldigesters
Probiotic supplements containing high β-galactosidase-producing bacteria may aid in the management of lactose intolerance. We previously isolated a strain of Bifidobacterium adolescentis, iVS-1, from the fecal sample of a human donor after consumption of galactooligosaccharides (GOS), a prebiotic de...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Gut Microbes Reports |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/29933935.2025.2508199 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850103805553672192 |
|---|---|
| author | Monica Ramakrishnan Tzu-Wen L. Cross Anna Clapp Organski Sindusha Mysore Saiprasad Abigayle M. R. Simpson Daniel J. Tancredi Mallory J. Van Haute Chloe M. Christensen Zachery T. Lewis Thomas A. Auchtung Jens Walter Robert Hutkins Dennis A. Savaiano |
| author_facet | Monica Ramakrishnan Tzu-Wen L. Cross Anna Clapp Organski Sindusha Mysore Saiprasad Abigayle M. R. Simpson Daniel J. Tancredi Mallory J. Van Haute Chloe M. Christensen Zachery T. Lewis Thomas A. Auchtung Jens Walter Robert Hutkins Dennis A. Savaiano |
| author_sort | Monica Ramakrishnan |
| collection | DOAJ |
| description | Probiotic supplements containing high β-galactosidase-producing bacteria may aid in the management of lactose intolerance. We previously isolated a strain of Bifidobacterium adolescentis, iVS-1, from the fecal sample of a human donor after consumption of galactooligosaccharides (GOS), a prebiotic derived from lactose. Therefore, it was hypothesized that iVS-1 might reduce symptoms associated with lactose maldigestion. Compared to other probiotic strains, iVS-1 had high β-galactosidase activity and reduced gas formation by fecal communities during in vitro fermentations of lactose or milk. A randomized placebo-controlled clinical trial was then conducted with 21 lactose maldigesters, randomized to receive either B. adolescentis iVS-1 (n = 11) or placebo (n = 10) daily for 2 weeks. Compared to the two-week run-in period, iVS-1 abundance was higher both at the end of the treatment period (p = 0.0005) and after the 2-week post-treatment period (p = 0.045). The iVS-1 group reported less overall daily symptoms during the treatment period when compared to placebo (p = 0.032) and had significant improvement for fecal urgency (p = 0.033) and diarrhea (p = 0.006). The metabolism of lactose, reduction of gas, and improvement of multiple gastrointestinal symptoms suggest that B. adolescentis iVS-1 may be an effective treatment for lactose intolerance.Trial Registration: The trial is registered at ClinicalTrials.gov (https://clinicaltrials.gov/study/NCT05668468). |
| format | Article |
| id | doaj-art-355f474a67a042de9893a53b1ee9ee3d |
| institution | DOAJ |
| issn | 2993-3935 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes Reports |
| spelling | doaj-art-355f474a67a042de9893a53b1ee9ee3d2025-08-20T02:39:28ZengTaylor & Francis GroupGut Microbes Reports2993-39352025-12-012110.1080/29933935.2025.2508199Two-week supplementation of Bifidobacterium adolescentis iVS-1 reduces symptoms associated with lactose intolerance in lactose maldigestersMonica Ramakrishnan0Tzu-Wen L. Cross1Anna Clapp Organski2Sindusha Mysore Saiprasad3Abigayle M. R. Simpson4Daniel J. Tancredi5Mallory J. Van Haute6Chloe M. Christensen7Zachery T. Lewis8Thomas A. Auchtung9Jens Walter10Robert Hutkins11Dennis A. Savaiano12Department of Nutrition Science, Purdue University, West Lafayette, IN, USADepartment of Nutrition Science, Purdue University, West Lafayette, IN, USADepartment of Nutrition Science, Purdue University, West Lafayette, IN, USADepartment of Nutrition Science, Purdue University, West Lafayette, IN, USADepartment of Nutrition Science, Purdue University, West Lafayette, IN, USADepartment of Pediatrics, UC Davis, Sacramento, CA, USASynbiotic Health, Lincoln, NE, USASynbiotic Health, Lincoln, NE, USALewpine Consulting LLC, American Fork, UT, USASynbiotic Health, Lincoln, NE, USASchool of Microbiology, Department of Medicine, and APC Microbiome Ireland, University College Cork, Cork, IrelandDepartment of Food Science and Technology, Nebraska Food for Health Center, University of Nebraska, Lincoln, NE, USADepartment of Nutrition Science, Purdue University, West Lafayette, IN, USAProbiotic supplements containing high β-galactosidase-producing bacteria may aid in the management of lactose intolerance. We previously isolated a strain of Bifidobacterium adolescentis, iVS-1, from the fecal sample of a human donor after consumption of galactooligosaccharides (GOS), a prebiotic derived from lactose. Therefore, it was hypothesized that iVS-1 might reduce symptoms associated with lactose maldigestion. Compared to other probiotic strains, iVS-1 had high β-galactosidase activity and reduced gas formation by fecal communities during in vitro fermentations of lactose or milk. A randomized placebo-controlled clinical trial was then conducted with 21 lactose maldigesters, randomized to receive either B. adolescentis iVS-1 (n = 11) or placebo (n = 10) daily for 2 weeks. Compared to the two-week run-in period, iVS-1 abundance was higher both at the end of the treatment period (p = 0.0005) and after the 2-week post-treatment period (p = 0.045). The iVS-1 group reported less overall daily symptoms during the treatment period when compared to placebo (p = 0.032) and had significant improvement for fecal urgency (p = 0.033) and diarrhea (p = 0.006). The metabolism of lactose, reduction of gas, and improvement of multiple gastrointestinal symptoms suggest that B. adolescentis iVS-1 may be an effective treatment for lactose intolerance.Trial Registration: The trial is registered at ClinicalTrials.gov (https://clinicaltrials.gov/study/NCT05668468).https://www.tandfonline.com/doi/10.1080/29933935.2025.2508199BifidobacteriaBifidobacterium adolescentisgalactooligosaccharideslactose digestionlactose intolerancegut microbiome |
| spellingShingle | Monica Ramakrishnan Tzu-Wen L. Cross Anna Clapp Organski Sindusha Mysore Saiprasad Abigayle M. R. Simpson Daniel J. Tancredi Mallory J. Van Haute Chloe M. Christensen Zachery T. Lewis Thomas A. Auchtung Jens Walter Robert Hutkins Dennis A. Savaiano Two-week supplementation of Bifidobacterium adolescentis iVS-1 reduces symptoms associated with lactose intolerance in lactose maldigesters Gut Microbes Reports Bifidobacteria Bifidobacterium adolescentis galactooligosaccharides lactose digestion lactose intolerance gut microbiome |
| title | Two-week supplementation of Bifidobacterium adolescentis iVS-1 reduces symptoms associated with lactose intolerance in lactose maldigesters |
| title_full | Two-week supplementation of Bifidobacterium adolescentis iVS-1 reduces symptoms associated with lactose intolerance in lactose maldigesters |
| title_fullStr | Two-week supplementation of Bifidobacterium adolescentis iVS-1 reduces symptoms associated with lactose intolerance in lactose maldigesters |
| title_full_unstemmed | Two-week supplementation of Bifidobacterium adolescentis iVS-1 reduces symptoms associated with lactose intolerance in lactose maldigesters |
| title_short | Two-week supplementation of Bifidobacterium adolescentis iVS-1 reduces symptoms associated with lactose intolerance in lactose maldigesters |
| title_sort | two week supplementation of bifidobacterium adolescentis ivs 1 reduces symptoms associated with lactose intolerance in lactose maldigesters |
| topic | Bifidobacteria Bifidobacterium adolescentis galactooligosaccharides lactose digestion lactose intolerance gut microbiome |
| url | https://www.tandfonline.com/doi/10.1080/29933935.2025.2508199 |
| work_keys_str_mv | AT monicaramakrishnan twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters AT tzuwenlcross twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters AT annaclapporganski twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters AT sindushamysoresaiprasad twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters AT abigaylemrsimpson twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters AT danieljtancredi twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters AT malloryjvanhaute twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters AT chloemchristensen twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters AT zacherytlewis twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters AT thomasaauchtung twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters AT jenswalter twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters AT roberthutkins twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters AT dennisasavaiano twoweeksupplementationofbifidobacteriumadolescentisivs1reducessymptomsassociatedwithlactoseintoleranceinlactosemaldigesters |